Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,472,100
  • Shares Outstanding, K 178,774
  • Annual Sales, $ 1,272 M
  • Annual Income, $ -245,030 K
  • EBIT $ -253 M
  • EBITDA $ -146 M
  • 60-Month Beta 4.90
  • Price/Sales 6.61
  • Price/Cash Flow N/A
  • Price/Book 17.07

Options Overview Details

View History
  • Implied Volatility 71.91% (-1.13%)
  • Historical Volatility 53.89%
  • IV Percentile 31%
  • IV Rank 15.37%
  • IV High 133.93% on 04/08/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 6) 3.42 (7.21%)
  • Put/Call Vol Ratio 0.52
  • Today's Volume 15,443
  • Volume Avg (30-Day) 17,710
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 287,033
  • Open Int (30-Day) 277,892
  • Expected Range 43.97 to 50.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.44
  • Number of Estimates 5
  • High Estimate $-0.36
  • Low Estimate $-0.58
  • Prior Year $-0.29
  • Growth Rate Est. (year over year) -51.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.73 +13.56%
on 03/30/26
53.63 -11.64%
on 03/11/26
-5.92 (-11.10%)
since 03/02/26
3-Month
41.73 +13.56%
on 03/30/26
76.33 -37.91%
on 01/12/26
-14.97 (-24.01%)
since 01/02/26
52-Week
36.22 +30.84%
on 04/09/25
104.32 -54.57%
on 10/09/25
-2.50 (-5.01%)
since 04/02/25

Most Recent Stories

More News
Bye Bye, AMD! Cathie Wood Ditches 57K Advanced Micro Shares

Cathie Wood offloads AMD along with a bunch of other tech stocks as she moves away from semiconductor.

NVDA : 177.39 (+0.93%)
META : 574.46 (-0.82%)
ROKU : 97.66 (+2.91%)
CRCL : 90.26 (-0.53%)
AMD : 217.50 (+3.47%)
$IUXX : 24,045.53 (+0.11%)
TEM : 47.39 (+0.77%)
TSM : 339.04 (-0.72%)
Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease

ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the undertreatment of significant valvular heart disease...

TEM : 47.39 (+0.77%)
Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit...

TEM : 47.39 (+0.77%)
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology...

TEM : 47.39 (+0.77%)
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded,...

TEM : 47.39 (+0.77%)
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom...

TEM : 47.39 (+0.77%)
Tempus: Q4 Earnings Snapshot

Tempus: Q4 Earnings Snapshot

TEM : 47.39 (+0.77%)
Tempus Reports Fourth Quarter and Full Year 2025 Results

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31,...

TEM : 47.39 (+0.77%)
2 Tech Bets Cathie Wood is Quietly Trimming Right Now: Should You Too?

Wood reduced her stake in these two tech bets but did not completely exit. What does that imply?

TER : 309.61 (-0.83%)
ARKW : 121.60 (+0.26%)
ARKQ : 114.90 (+0.34%)
PINS : 18.18 (-0.60%)
TEM : 47.39 (+0.77%)
Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents...

TEM : 47.39 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 52.92
2nd Resistance Point 50.51
1st Resistance Point 48.95
Last Price 47.39
1st Support Level 44.98
2nd Support Level 42.57
3rd Support Level 41.01

See More

52-Week High 104.32
Fibonacci 61.8% 78.31
Fibonacci 50% 70.27
Fibonacci 38.2% 62.23
Last Price 47.39
52-Week Low 36.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.